SUN-062 Randomized Controlled Trial for Assessment of the Effects of Anaglipitin, a DPP-4 Inhibitor, on Blood Lipids in Type 2 Diabetic Patients

Background and aims: Dyslipidemia, which is associated with type 2 diabetes, additively increases cardiovascular complications. To date several incretin drugs have been reported to improve lipid metabolism. Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and has been reported to improve the...

Descripción completa

Detalles Bibliográficos
Autores principales: Onoue, Takeshi, Goto, Motomitsu, Furukawa, Mariko, Wada, Eri, Okuji, Takayuki, Okada, Norio, Kobayashi, Tomoko, Yasuda, Yoshinori, Iwama, Shintaro, Ando, Masahiko, Arima, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Cardiovascular Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553206/
http://dx.doi.org/10.1210/js.2019-SUN-062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553206/
http://dx.doi.org/10.1210/js.2019-SUN-062

Ejemplares similares